3451 studies found for:    "Carcinoma, Non-Small-Cell Lung"
Show Display Options
Rank Status Study
1 Recruiting Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer
Conditions: Carcinoma, Non-Small-Cell Lung;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer
Interventions: Drug: vitamin C;   Device: Modulated Electro-Hyperthermia (mEHT);   Other: Supportive care
2 Completed Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Conditions: Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer
Interventions: Drug: CC-223, erlotinib;   Drug: CC-223, oral azacitidine
3 Active, not recruiting Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
Conditions: Non-Small-Cell Lung Cancer Stage IIIB;   Non-Small-Cell Lung Cancer Stage IV;   Non-Small-Cell Lung Cancer Metastatic;   Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer;   Non-Small-Cell Lung Carcinoma;   Nonsmall Cell Lung Cancer
Interventions: Biological: bavituximab;   Drug: Docetaxel;   Other: Placebo (for bavituximab)
4 Completed Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer
Conditions: Non-Small-Cell Lung Carcinoma;   Carcinoma, Non-Small Cell Lung;   Lung Neoplasms
Intervention: Drug: EKB-569
5 Completed FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer
Intervention: Drug: FR901228
6 Recruiting Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
Conditions: Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer;   Nonsmall Cell Lung Cancer
Intervention: Drug: Nintedanib
7 Withdrawn Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)
Conditions: Carcinoma, Non-Small-Cell-Lung;   Non-Small Cell Lung Cancer;   Nonsmall Cell Lung Cancer
Interventions: Procedure: Standard of care surgery;   Procedure: Apheresis;   Drug: Cyclophosphamide;   Biological: Personalized mature dendritic cell vaccine
8 Unknown  Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer;   Lung Cancer;   Stage IIIA Non Small Cell Lung Cancer;   Stage IIIB Non Small Cell Lung Cancer
Intervention: Drug: S-3304
9 Recruiting Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Conditions: Non-small Cell Lung Cancer;   Advanced Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Hydroxychloroquine;   Drug: Bevacizumab
10 Recruiting Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation
Conditions: Cachexia;   Fatigue;   Pulmonary Complications;   Radiation Toxicity;   Recurrent Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Behavioral: exercise intervention;   Procedure: pulmonary complications management/prevention;   Procedure: quality-of-life assessment;   Other: questionnaire administration
11 Terminated Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy
Conditions: Carcinoma, Non-small Cell Lung;   Lung Cancer
Intervention: Drug: Satraplatin
12 Active, not recruiting Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Progression of Non-small Cell Lung Cancer;   Non-small Cell Lung Cancer Recurrent
Interventions: Drug: Docetaxel;   Biological: HyperAcute®-Lung Immunotherapy;   Drug: Gemcitabine;   Drug: Pemetrexed
13 Completed Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)
Conditions: Non-small Cell Lung Cancer Stage I;   Non-small Cell Lung Cancer Stage II;   Non-small Cell Lung Cancer Stage IIIA
Intervention:
14 Recruiting Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Progression of Non-small Cell Lung Cancer;   Non-small Cell Lung Cancer Recurrent
Interventions: Drug: Docetaxel;   Biological: Tergenpumatucel-L;   Drug: Indoximod 600mg;   Drug: Indoximod 1200mg
15 Terminated Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer Stage IIIB;   Non-small Cell Lung Cancer Stage IV;   Non-small Cell Lung Cancer Metastatic
Interventions: Drug: Docetaxel;   Drug: Combination of ganetespib and docetaxel
16 Active, not recruiting A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: MM-121 (SAR256212) + erlotinib;   Drug: Erlotinib
17 Completed
Has Results
Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Biological: cixutumumab;   Drug: carboplatin;   Drug: paclitaxel;   Biological: cetuximab
18 Completed Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)
Conditions: Carcinoma, Non-Small-Cell Lung;   Non-small Cell Lung Cancer;   NSCLC
Interventions: Drug: Erlotinib (tarceva);   Drug: Placebo
19 Recruiting Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: CC-486;   Drug: Pembrolizumab;   Drug: Placebo
20 Completed Pharmacogenomic Study Realized on "Non-small Cell Lung Carcinoma"
Condition: Carcinoma, Non-Small-Cell Lung
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years